RadNet lists ultrasound biomarker study for resmetirom eligibility, not yet recruiting

RadNet Management had one notable registry entry during the week of October 6, 2026.

• A study titled "Accuracy of Ultrasound Biomarkers for Assessing Eligibility and Response to Resmetirom Therapy Using MRI as the Reference Standard" was listed on ClinicalTrials.gov on October 6, 2026, with status "not yet recruiting." The study is a prospective, non-interventional, observational study to evaluate the accuracy of 2 ultrasound biomarkers, UDFF and pSWE, for determining MRI-defined eligibility for resmetirom treatment and for monitoring treatment response using MRI-PDFF and MRE as reference standards.¹ Madrigal Pharmaceuticals and Siemens Medical Solutions are listed as collaborators. The estimated start is October 2026, with primary completion estimated for October 2028.